Boston Scientific’s “blockbuster” Synergy stent for opening blocked arteries on the heart commands a higher price than its competitors, but so far the jury is out on whether it can prevent long-term problems seen in lower-priced models.
Company executives are confident that their Minnesota-designed Synergy drug-eluting stent, which is coated on the outside with a one-of-a-kind biodegradable polymer, will eventually show its value as the years progress for thousands of patients in an ongoing clinical trial. The material is absorbed by the body, theoretically cutting health problems linked to coatings that linger for years on stents like Medtronic’s Resolute Integrity.
Company executives are confident that their Minnesota-designed Synergy drug-eluting stent, which is coated on the outside with a one-of-a-kind biodegradable polymer, will eventually show its value as the years progress for thousands of patients in an ongoing clinical trial. The material is absorbed by the body, theoretically cutting health problems linked to coatings that linger for years on stents like Medtronic’s Resolute Integrity.
